Drugs / ENV-501
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06956690 | Dec 2025 → Jul 2027 expected | breast cancer, cutaneous melanoma, non-small cell lung carcinoma | Hummingbird Bioscience | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ENV-501 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06956690 ↗ |
| Modality | Monoclonal antibody | “humanized monoclonal antibody (mAb)” NCT06956690 ↗ |
| Route | Intravenous | “HMBD-501 intravenous injection once every 3 weeks; successive cohorts will receive escalating doses of HMBD-501 until the RP2D is reached” NCT06956690 ↗ |